NCT02413645View on ClinicalTrials.gov

Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

October 31, 2016

Conditions
HIV-infection
Interventions
BIOLOGICAL

TriMix_100

100 μg of TriMix in

BIOLOGICAL

TriMix_300

300 μg of TriMix in

BIOLOGICAL

600μg mRNA (300 μg HIV mRNA+300 μg TriMix mRNA)

600 μg of mRNA (300 μg TriMix + 300 μg HIVACAT)

BIOLOGICAL

900μg mRNA (600 μg HIV mRNA+300 μg TriMix mRNA)

900 μg of mRNA (300 μg TriMix + 600 μg HIVACAT)

BIOLOGICAL

1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA)

1200 μg of mRNA (300 μg TriMix + 900 μg HIVACAT)

Trial Locations (1)

08036

Hospital Clínic de Bacelona, Barcelona

All Listed Sponsors
lead

Judit Pich Martínez

OTHER

NCT02413645 - Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients | Biotech Hunter | Biotech Hunter